Item 2.02 Results of Operation and Financial Condition.

2seventy bio, Inc. (the "Company") intends to share with investors the amount of cash, cash equivalents and marketable securities it had on hand as of December 31, 2022 and the revenue received from sales of ABECMA in the U.S. for the year ended December 31, 2022. Although the Company has not finalized its financial results for the twelve months ended December 31, 2022, the Company currently anticipates that its cash, cash equivalents and marketable securities were approximately $268 million as of December 31, 2022 and that revenue from sales of ABECMA in the U.S. in 2022 equaled approximately $250 to $300 million, which is shared equally with Bristol-Myers Squibb. This information is unaudited and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2022 and its results of operations for the twelve months ended December 31, 2022. The Company expects to announce its full results for the twelve months ended December 31, 2022 on or before March 31, 2023.




Item 7.01  Regulation FD Disclosure.

The Company from time to time presents and distributes to investors slide presentations to provide updates and summaries of its business. A copy of its current presentation is being furnished as Exhibit 99.1, which is incorporated herein by reference.

The information in this Current Report on Form 8-K pursuant to Item 7.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this Current Report.

Item 8.01 Other Events.

On January 9, 2023, the Company issued a press release announcing key milestone updates and providing other business highlights.

The full text of the press release regarding the announcement is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits

    Exhibit
      No.                                              Description
      99.1               Slide presentation of 2seventy bio, Inc. furnished herewith.
      99.2               Press release issued by 2seventy bio, Inc. on January 9, 2023.
      104              Cover Page Interactive Data File (embedded within the Inline XBRL document
                       and incorporated as Exhibit 101)


____________

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses